Chemical proteomics reveals that the anticancer drug everolimus affects ubiquitin-proteasome system
A. A. Lobas, A. A. Saei, H. Lyu, R. A. Zubarev, M. V. Gorshkov
This study shows that everolimus, a rapamycin analog, uniquely affects the ubiquitin-proteasome system by increasing ubiquitin levels and altering polyubiquitination patterns, distinct from its analogs.
bioRxiv · Oct 15, 2023Cancer Biology